Adicet Bio Inactive 10-Q8 Nov 132014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'ACET	'
Entity Registrant Name	'ACETO CORP	'
Entity Central Index Key	'0000002034	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	28,135,375

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$35,058	$33,231
Investments	2,165	2,144
Trade receivables, less allowance for doubtful accounts (September, $1,427; June, $1,294)	93,197	90,108
Other receivables	6,590	5,283
Inventory	87,266	83,849
Prepaid expenses and other current assets	3,885	2,984
Deferred income tax asset, net	726	701
Total current assets	228,887	218,300
Property and equipment, net	11,449	11,410
Property held for sale	4,058	4,058
Goodwill	33,563	33,526
Intangible assets, net	39,426	40,831
Deferred income tax asset, net	8,057	8,055
Other assets	7,822	7,250
TOTAL ASSETS	333,262	323,430
Current liabilities:	'	'
Current portion of long-term debt	7,947	11,714
Accounts payable	41,588	39,222
Accrued expenses	40,132	38,971
Total current liabilities	89,667	89,907
Long-term debt	18,306	20,355
Long-term liabilities	12,217	13,413
Environmental remediation liability	4,615	5,109
Deferred income tax liability	19	6
Total liabilities	124,824	128,790
Commitments and contingencies (Note 6)	'	'
Shareholders' equity:	'	'
Common stock, $.01 par value, 40,000 shares authorized; 28,135 and 27,831 shares issued and outstanding at September 30, 2013 and June 30, 2013, respectively	281	278
Capital in excess of par value	74,911	72,845
Retained earnings	128,263	118,615
Accumulated other comprehensive income	4,983	2,902
Total shareholders' equity	208,438	194,640
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$333,262	$323,430

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Trade receivables, allowance for doubtful accounts	$1,427	$1,294
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	40,000	40,000
Common stock, shares issued	28,135	27,831
Common stock, shares outstanding	28,135	27,831

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'
Net sales	$129,261	$111,748
Cost of sales	95,527	90,243
Gross profit	33,734	21,505
Selling, general and administrative expenses	15,764	12,987
Research and development expenses	554	905
Operating income	17,416	7,613
Other income (expense):	'	'
Interest expense	-453	-546
Interest and other income, net	611	555
Nonoperating income expense	158	9
Income before income taxes	17,574	7,622
Income tax provision	6,239	2,802
Net income (loss)	$11,335	$4,820
Net income per common share	$0.41	$0.18
Diluted net income per common share	$0.40	$0.18
Weighted average shares outstanding:	'	'
Basic	27,757	26,805
Diluted	28,390	27,229

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Statement Of Income And Comprehensive Income [Abstract]	'	'
Net income	$11,335	$4,820
Other comprehensive income:	'	'
Foreign currency translation adjustments	2,050	1,042
Change in fair value of interest rate swaps	31	-5
Comprehensive income	$13,416	$5,857

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities:	'	'
Net income	$11,335	$4,820
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	1,774	1,725
Provision for doubtful accounts	70	37
Non-cash stock compensation	798	444
Deferred income taxes	6	-64
Earnings on equity investment in joint venture	-313	-324
Changes in assets and liabilities:	'	'
Trade accounts receivable	-2,224	-1,597
Other receivables	-1,082	618
Inventory	-2,356	-484
Prepaid expenses and other current assets	-826	-548
Other assets	-11	-37
Accounts payable	1,992	-4,273
Accrued expenses and other liabilities	-1,153	-3,259
Net cash provided by (used in) operating activities	8,010	-2,942
Investing activities:	'	'
Purchases of investments	-56	-32
Sales of investments	'	1,002
Payments for intangible assets	'	-171
Purchases of property and equipment, net	-356	-327
Net cash (used in) provided by investing activities	-412	472
Financing activities:	'	'
Payment of cash dividends	-1,665	-1,477
Proceeds from exercise of stock options	861	576
Excess tax benefit on stock option exercises and restricted stock	232	158
Borrowings of bank loans	'	4,000
Repayment of bank loans	-5,816	-1,548
Net cash (used in) provided by financing activities	-6,388	1,709
Effect of exchange rate changes on cash	617	242
Net increase (decrease) in cash	1,827	-519
Cash at beginning of period	33,231	24,862
Cash at end of period	$35,058	$24,343

Basis_of_Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	(1) Basis of Presentation

	The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year.

	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; royalty income; partnered products; allowance for doubtful accounts; inventories; goodwill and other indefinite-lived intangible assets; long-lived assets; environmental and other contingencies; income taxes; and stock-based compensation.

	These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2013.

	Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current year presentation.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	(2) Stock-Based Compensation

	At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company’s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (2010 Plan). Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses (collectively, “Stock Awards”) may be made to employees, non-employee directors and consultants of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.

	During the three months ended September 30, 2013, the Company granted 199 shares of restricted common stock to its employees that vest over three years, as well as 32 restricted stock units that have varying vest dates from December 2013 through July 2015. In addition, the Company also issued a target grant of 131 performance-vested restricted stock units, which grant could be as much as 196 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

	During the year ended June 30, 2013, the Company granted 120 shares of restricted common stock to its employees that vest over three years and 25 shares of restricted common stock to its non-employee directors, which vest over one year. In addition, the Company also issued a target grant of 84 performance-vested restricted stock units, which grant could be as much as 126 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.


	For the three months ended September 30, 2013 and 2012, the Company recorded stock-based compensation expense of approximately $716 and $358 respectively, related to restricted common stock and restricted stock units. As of September 30, 2013, the total unrecognized compensation cost related to restricted stock awards and units is approximately $6,544. There were no stock options granted in the three months ended September 30, 2013 and 2012. Total compensation expense related to stock options for the three months ended September 30, 2013 and 2012 was $79 and $83, respectively. As of September 30, 2013, the total unrecognized compensation cost related to option awards is $158.

Common_Stock

Common Stock	3 Months Ended
Common Stock	Sep. 30, 2013
Equity [Abstract]	'
Common Stock	'
	(3) Common Stock

	On August 28, 2013, the Company’s board of directors declared a regular quarterly dividend of $0.06 per share which was paid on September 27, 2013 to shareholders of record as of September 16, 2013.

Net_Income_Per_Common_Share

Net Income Per Common Share	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Income Per Common Share	'
	(4) Net Income Per Common Share

	Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding:

		Three months ended
		September 30,
		2013		2012

	Weighted average shares outstanding		27,757		26,805
	Dilutive effect of stock options and restricted stock awards and units		633		424
	Diluted weighted average shares outstanding		28,390		27,229

	There were 0 and 587 common equivalent shares outstanding as of September 30, 2013 and 2012, respectively, that were not included in the calculation of diluted income per common share for the three months ended September 30, 2013 and 2012, respectively, because their effect would have been anti-dilutive.

Debt

Debt	3 Months Ended
Debt	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt	'
	(5) Debt

	Long-term debt

		September 30,		June 30,
		2013		2013

	Term bank loans	$	22,750	$	24,500
	Revolving bank loans		-		4,000
	Mortgage		3,503		3,569
			26,253		32,069
	Less current portion		7,947		11,714
		$	18,306	$	20,355



	Credit Facilities

	On December 31, 2010, the Company entered into a Credit Agreement (the “Credit Agreement”) with two U.S. financial institutions. The Credit Agreement terminated the Amended and Restated Credit Agreement, dated April 23, 2010. Aceto may borrow, repay and reborrow during the period ending December 31, 2015, up to but not exceeding at any one time outstanding $40,000 (the “Revolving Loans”). The Revolving Loans may be (i) Adjusted LIBOR Loans (as defined in the Credit Agreement), (ii) Alternate Base Rate Loans (as defined in the Credit Agreement) or (iii) a combination thereof. As of September 30, 2013, there were no Revolving Loans outstanding. The Credit Agreement also allows for the borrowing of up to $40,000 (the “Term Loan”). The Company borrowed a Term Loan of $40,000 on December 31, 2010. The Term Loan interest may be payable as an (i) Adjusted LIBOR Loan, (ii) Alternate Base Rate Loan, or (iii) a combination thereof. As of September 30, 2013, the remaining amount outstanding under the original amortizing Term Loan is $22,750 and is payable as an Adjusted LIBOR Loan at an interest rate of 2.0% at September 30, 2013. The Term Loan is payable as to principal in twenty (20) consecutive quarterly installments, which commenced on March 31, 2011 and will continue on each June 30, September 30 and December 31st thereafter, each in the amount set forth below opposite the applicable installment, provided that the final payment on the Term Loan Maturity Date (as defined in the Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Term Loan:

	Installment	Amount

	1 through 8	$	1,500
	9 through 12	$	1,750
	13 through 16	$	2,000
	17 through 20	$	3,250

	As such, the Company has classified $7,750 of the Term Loan as short-term in the consolidated balance sheet at September 30, 2013. The Credit Agreement also provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services by the Company in the ordinary course of business. The Company had open letters of credit of approximately $245 and $78 as of September 30, 2013 and June 30, 2013, respectively. The terms of these letters of credit are all less than one year. No material loss is anticipated due to non-performance by the counterparties to these agreements.

	The Credit Agreement provides for a security interest in all personal property of the Company. The Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service. The Company is also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on cash dividends, guarantees, sale of assets, sales of receivables, and loans and investments. The Company was in compliance with all covenants at September 30, 2013.

	Mortgage

	On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its new corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable bears interest at 5.92% as of September 30, 2013 and matures on June 30, 2021.

Commitments_Contingencies_and_

Commitments, Contingencies and Other Matters	3 Months Ended
Commitments, Contingencies and Other Matters	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments, Contingencies and Other Matters	'
	(6) Commitments, Contingencies and Other Matters

	The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The impact of the final resolution of these matters on the Company’s results of operations in a particular reporting period is not known.


	On October 29, 2012, a lawsuit was filed in the United Kingdom (in the High Court of Justice, Queens Bench Division, Commercial Court) by United Phosphorous Limited (“UPL”) against Aceto Agricultural Chemicals Corporation (“AACC”), a wholly-owned subsidiary of the Company. In the lawsuit, UPL alleges, among other things, that AACC breached a 1995 agreement regarding European sales of a potato sprout suppression product, by selling the product in Europe. UPL claims damages of approximately £4,500 (approximately US $7,200) plus an unspecified amount of additional damages. While the impact of the resolution of the matter, including any legal and other associated costs, on the Company’s consolidated results of operations in a particular reporting period is not known at this time, after a detailed review and careful analysis of the allegations, AACC strongly denies the allegations, believes that UPL’s claims are without merit and intends to vigorously defend the lawsuit.

	In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimus contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not known. However, management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company’s financial condition or liquidity.

	The Company has environmental remediation obligations in connection with Arsynco, Inc. (Arsynco), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, the Company received an estimate from an environmental consultant stating that the costs of remediation could be between $9,000 and $10,800. Remediation commenced in fiscal 2010, and as of September 30, 2013 and June 30, 2013, a liability of $6,673 and $7,166, respectively, is included in the accompanying consolidated balance sheets for this matter. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

	In connection with the environmental remediation obligation for Arsynco, in July 2009, the Company entered into a settlement agreement with BASF Corporation (BASF), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract states that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of September 30, 2013 and June 30, 2013 is $3,003 and $3,225, respectively, which is included in the accompanying consolidated balance sheets.


	In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area. Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry’s Creek; any such claim with respect to Berry’s Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the “NJDEP Litigation”) and were considering impleading Arsynco into same. Arsynco entered into agreement to avoid impleader. Pursuant to agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not known.

	A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $4,501 through fiscal 2014.

	On December 31, 2010, the Company acquired certain assets of Rising Pharmaceuticals, Inc. (“Rising”), a New Jersey based company that markets and distributes generic prescription and over the counter pharmaceutical products to leading wholesalers, chain drug stores, distributors, mass market merchandisers and others under its own label, throughout the United States. The purchase agreement provides for the payment of additional contingent consideration equal to one-half of the three year cumulative Rising earnings before interest, taxes, depreciation and amortization in excess of $32,100, up to a maximum of $6,000. As of September 30, 2013, the Company has accrued $5,473 related to this contingent consideration. Any necessary future adjustments to this amount will be recorded as an income statement charge at that time.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	(7) Fair Value Measurements

	GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels:


	Level 1 – Quoted market prices in active markets for identical assets or liabilities;



	Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and


	Level 3 – Unobservable inputs that are not corroborated by market data.


	On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency forward contracts (futures) to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable forward foreign exchange rates. At September 30, 2013 the Company had foreign currency contracts outstanding that had a notional amount of $64,378. Unrealized gains (losses) on hedging activities for the three months ended September 30, 2013 and 2012 was $381 and ($61), respectively, and are included in interest and other income, net, in the condensed consolidated statements of income. The contracts have varying maturities of less than one year.

	Pursuant to the requirements of the Credit Agreement, the Company is required to deliver Hedging Agreements (as defined in the Credit Agreement) fixing the interest rate on not less than $20,000 of the Term Loan. Accordingly, in March 2011, the Company entered into an interest rate swap for a notional amount of $20,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 31, 2015. The unrealized loss to date associated with this derivative, which is recorded in accumulated other comprehensive income in the condensed consolidated balance sheet at September 30, 2013, is $227. The remaining balance of this derivative as of September 30, 2013 is $11,250. Aceto’s interest rate swap is classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.

	As of September 30, 2013 and June 30, 2013, the Company had $5,473 and $5,346, respectively, of contingent consideration that was recorded at fair value in the Level 3 category, which related to the acquisition of Rising, which was completed during fiscal 2011. The contingent consideration was calculated using the present value of a probability weighted income approach.

	During the fourth quarter of each year, the Company evaluates goodwill and indefinite-lived intangibles for impairment at the reporting unit level using an undiscounted cash flow model using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value. Measurements based on undiscounted cash flows are considered to be Level 3 inputs.


	The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at September 30, 2013 and June 30, 2013:

			Fair Value Measurements at September 30, 2013 Using

			Quoted Prices		Significant			Significant
			in Active		Other			Unobservable
			Markets		Observable			Inputs
			(Level 1)		Inputs (Level 2)			(Level 3)		Total

	Cash equivalents:
	Time deposits			-	$	867			-	$	867

	Investments:
	Time deposits			-		2,165			-		2,165

	Foreign currency contracts-assets (1)			-		461			-		461
	Foreign currency contracts-liabilities (2)			-		81			-		81
	Derivative liability for interest rate swap (3)			-		227			-		227
	Contingent consideration (4)			-		-		$	5,473		5,473

	-1	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
	(2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
	(3) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
	-4	$3,000 included in “Accrued expenses” and $2,473 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.

			Fair Value Measurements at June 30, 2013 Using

			Quoted Prices		Significant			Significant		Total
			in Active		Other			Unobservable
			Markets		Observable			Inputs
			(Level 1)		Inputs (Level 2)			(Level 3)

	Cash equivalents:
	Time deposits			-	$	856			-	$	856

	Investments:
	Time deposits			-		2,144			-		2,144

	Foreign currency contracts-assets (5)			-		14			-		14
Foreign currency contracts-liabilities (6)			-		173			-		173
Derivative liability for interest rate swap (7)			-		258			-		258
Contingent consideration (8)			-		-		$	5,346		5,346

-5	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
-6	Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
-7	Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
-8	$1,500 included in “Accrued expenses” and $3,846 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.


The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2013
Accounting Changes And Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	(8) Recent Accounting Pronouncements

	In July 2012, the FASB issued ASU 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment (the revised standard)” , which allows companies the option to perform a qualitative assessment to determine whether further impairment testing of indefinite-lived intangible assets is necessary. Under this guidance, an entity is required to perform a quantitative impairment test if qualitative factors indicate that it is more likely than not that indefinite-lived intangible assets are impaired. The qualitative factors are consistent with the guidance established for goodwill impairment testing and include identifying and assessing events and circumstances that would most significantly impact, individually or in the aggregate, the carrying value of the indefinite-lived intangible assets. The revised standard is effective for the Company in fiscal 2014 and early adoption is permitted. The adoption of ASU 2012 -02 is not expected to have a material impact on the Company’s consolidated financial statements.

Segment_Information

Segment Information	3 Months Ended
Segment Information	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	(9) Segment Information

	The Company’s business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

	Human Health - includes finished dosage form generic drugs and nutraceutical products.

	Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

	Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agriculture Protection Products. Specialty chemicals includes a variety of chemicals which make plastics, surface coatings, textiles, fuels and lubricants perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals. In addition, Aceto is a supplier of diazos and couplers to the paper, film and electronics industries.

	Agricultural Protection Products includes herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. The Agricultural Protection Products segment also includes a sprout inhibitor for potatoes and an herbicide for sugar cane.

	The Company’s chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments’ performance, as the assets are managed on an entity-wide basis.


	Three Months Ended September 30, 2013 and 2012:

		Human		Pharmaceutical		Performance		Unallocated			Consolidated
		Health		Ingredients		Chemicals		Corporate			Totals
	2013
	Net sales	$	38,694	$	48,424	$	42,143	$	-		$	129,261
	Gross profit		11,141		15,262		7,331		-			33,734
	Income before income taxes		5,535		11,004		3,302		(2,267	)		17,574

	2012
	Net sales	$	26,409	$	40,608	$	44,731	$	-		$	111,748
	Gross profit		8,103		6,576		6,826		-			21,505
	Income before income taxes		3,119		2,553		3,085		(1,135	)		7,622

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding	'
	The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding:

		Three months ended
		September 30,
		2013		2012

	Weighted average shares outstanding		27,757		26,805
	Dilutive effect of stock options and restricted stock awards and units		633		424
	Diluted weighted average shares outstanding		28,390		27,229

Debt_Tables

Debt (Tables)	3 Months Ended
Debt (Tables)	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt	'
	Long-term debt

		September 30,		June 30,
		2013		2013

	Term bank loans	$	22,750	$	24,500
	Revolving bank loans		-		4,000
	Mortgage		3,503		3,569
			26,253		32,069
	Less current portion		7,947		11,714
		$	18,306	$	20,355
Schedule of Outstanding Unpaid Principal Amount of the Term Loan	'
	The Term Loan is payable as to principal in twenty (20) consecutive quarterly installments, which commenced on March 31, 2011 and will continue on each June 30, September 30 and December 31st thereafter, each in the amount set forth below opposite the applicable installment, provided that the final payment on the Term Loan Maturity Date (as defined in the Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Term Loan:

	Installment	Amount

	1 through 8	$	1,500
	9 through 12	$	1,750
	13 through 16	$	2,000
	17 through 20	$	3,250

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Summary of Valuation of the Company's Financial Assets and Liabilities	'
	The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at September 30, 2013 and June 30, 2013:

			Fair Value Measurements at September 30, 2013 Using

			Quoted Prices		Significant		Significant
			in Active		Other		Unobservable
			Markets		Observable		Inputs
			(Level 1)		Inputs (Level 2)		(Level 3)		Total

	Cash equivalents:
	Time deposits			-	$	867		-	$	867

	Investments:
	Time deposits			-		2,165		-		2,165

	Foreign currency contracts-assets (1)			-		461		-		461
	Foreign currency contracts-liabilities (2)			-		81		-		81
	Derivative liability for interest rate swap (3)			-		227		-		227
	Contingent consideration (4)			-		-	$	5,473		5,473

	-1	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
	(2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
	(3) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
	-4	$3,000 included in “Accrued expenses” and $2,473 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.

			Fair Value Measurements at June 30, 2013 Using

			Quoted Prices		Significant		Significant		Total
			in Active		Other		Unobservable
			Markets		Observable		Inputs
			(Level 1)		Inputs (Level 2)		(Level 3)

	Cash equivalents:
	Time deposits			-	$	856		-	$	856

	Investments:
	Time deposits			-		2,144		-		2,144

	Foreign currency contracts-assets (5)			-		14		-		14
	Foreign currency contracts-liabilities (6)			-		173		-		173
	Derivative liability for interest rate swap (7)			-		258		-		258
	Contingent consideration (8)			-		-	$	5,346		5,346

	-5	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
	-6	Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
	-7	Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
	-8	$1,500 included in “Accrued expenses” and $3,846 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Performance Measures	'
	Three Months Ended September 30, 2013 and 2012:

		Human		Pharmaceutical		Performance		Unallocated			Consolidated
		Health		Ingredients		Chemicals		Corporate			Totals
	2013
	Net sales	$	38,694	$	48,424	$	42,143	$	-		$	129,261
	Gross profit		11,141		15,262		7,331		-			33,734
	Income before income taxes		5,535		11,004		3,302		(2,267	)		17,574

	2012
	Net sales	$	26,409	$	40,608	$	44,731	$	-		$	111,748
	Gross profit		8,103		6,576		6,826		-			21,505
	Income before income taxes		3,119		2,553		3,085		(1,135	)		7,622

Stock_Based_Compensation_Narra

Stock Based Compensation (Narrative) (Detail) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 06, 2012

Sep. 30, 2013

Restricted Stock [Member]

Performance Shares [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock and Restricted Stock Units [Member]

Employee Stock Option [Member]

2010 Plan [Member]

Employees [Member]

Non Employee Directors [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Maximum number of shares of common stock that may be issued

5,250

Common stock granted, vesting period

'3 years

'1 year

'3 years

Common stock granted, shares

199

120

131

Common stock granted, vesting year

'2013-12

'2015-07

Upper limit of target grant, shares

196

126

Performance-vested restricted stock units, vesting percentage

100.00%

Stock-based compensation expense

$716

$358

$79

$83

Total unrecognized compensation cost

6,544

Stock options granted, shares

Total unrecognized compensation cost related to option awards

$158

Common_Stock_Narrative_Detail

Common Stock (Narrative) (Detail) (USD $)	3 Months Ended
Common Stock (Narrative) (Detail) (USD $)	Sep. 30, 2013
Equity [Abstract]	'
Dividends declared, per share	$0.06
Dividends declared, date of declaration	28-Aug-13
Dividends declared, date of record	16-Sep-13
Dividends declared, date of distribution	27-Sep-13

Net_Income_Per_Common_Share_Sc

Net Income Per Common Share (Schedule of Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Accounting Policies [Abstract]	'	'
Weighted average shares outstanding	27,757	26,805
Dilutive effect of stock options and restricted stock awards and units	633	424
Diluted weighted average shares outstanding	28,390	27,229

Net_Income_Per_Common_Share_Na

Net Income Per Common Share (Narrative) (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'
Common equivalent shares outstanding excluded from calculation of diluted income per common share because their effect would have been anti-dilutive	0	587

Debt_Schedule_of_Longterm_Debt

Debt (Schedule of Long-term Debt) (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013
Debt Instrument [Line Items]	'	'
Mortgage	$3,503	$3,569
Long-term debt including current portion	26,253	32,069
Less current portion	7,947	11,714
Long-term debt	18,306	20,355
Term Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Bank loans	22,750	24,500
Less current portion	7,750	'
Revolving Loans [Member]	'	'
Debt Instrument [Line Items]	'	'
Bank loans	'	$4,000

Debt_Narrative_Detail

Debt (Narrative) (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2010	Dec. 31, 2010	Jun. 30, 2011	Sep. 30, 2013
In Thousands, unless otherwise specified			Revolving Loans [Member]	Revolving Loans [Member]	Term Loan [Member]	Term Loan [Member]	Term Loan [Member]	Term Loan [Member]	Mortgage Payable [Member]	Mortgage Payable [Member]
					Installment			Rising Pharmaceuticals Inc. [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Revolving loans, maximum amount	'	'	$40,000	'	'	'	$40,000	'	'	'
Revolving loans, expiration date	'	'	31-Dec-15	'	'	'	'	'	'	'
Proceeds from term loans used to finance business acquisition	'	'	'	'	'	'	'	40,000	'	'
Bank loans outstanding	'	'	'	4,000	22,750	24,500	'	'	'	'
Bank loans, interest rate	'	'	'	'	2.00%	'	'	'	'	5.92%
Term loans, number of installments	'	'	'	'	20	'	'	'	'	'
Short term loans payable	7,947	11,714	'	'	7,750	'	'	'	'	'
Open letters of credit	245	78	'	'	'	'	'	'	'	'
Mortgage payable	$3,503	$3,569	'	'	'	'	'	'	$3,947	'
Mortgage payable, amortization period	'	'	'	'	'	'	'	'	'20 years	'

Debt_Schedule_of_Quarterly_Ins

Debt (Schedule of Quarterly Installments of Term Loans) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Term Loan Installments 1 through 8 [Member]	'
Debt Instrument [Line Items]	'
Periodic installment amount	$1,500
Term Loan Installments 9 through 12 [Member]	'
Debt Instrument [Line Items]	'
Periodic installment amount	1,750
Term Loan Installments 13 through 16 [Member]	'
Debt Instrument [Line Items]	'
Periodic installment amount	2,000
Term Loan Installments 17 through 20 [Member]	'
Debt Instrument [Line Items]	'
Periodic installment amount	$3,250

Commitments_Contingencies_and_1

Commitments, Contingencies and Other Matters (Narrative) (Detail)

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Jun. 30, 2013

Jun. 30, 2009

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

In Thousands, unless otherwise specified

Entity

Rising Pharmaceuticals Inc. [Member]

United Phosphorous Limited [Member]

Pulvair Site Group [Member]

Arsynco Inc. [Member]

BASF Corporation [Member]

Subsidiary [Member]

USD ($)

GBP (£)

USD ($)

Commitments and Contingencies Disclosure [Line Items]

Loss contingency, damages sought

$7,200

£ 4,500

$1,700

Site contingency loss exposure not accrued, low estimate

9,000

Site contingency loss exposure not accrued, high estimate

10,800

Accrual for environmental loss contingencies

6,673

7,166

Partial reimbursement of environmental remediation costs previously expensed

550

Environmental remediation costs expensed in prior years

1,200

Future remediation costs receivable

3,003

3,225

Number of potentially responsible parties

150

Amount expected to be paid for product registrations and various task force groups

4,501

Earnings before Interest taxes, depreciation and amortization

32,100

Contingent consideration, maximum

6,000

Contingent consideration at fair value

$5,473

$5,346

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Detail) (USD $)	3 Months Ended			3 Months Ended		1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2011	Sep. 30, 2013
		Rising Pharmaceuticals Inc. [Member]	Rising Pharmaceuticals Inc. [Member]	Foreign Currency Contract [Member]	Foreign Currency Contract [Member]	Interest Rate Swap [Member]	Interest Rate Swap [Member]
						Cash Flow Hedging [Member]	Cash Flow Hedging [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'	'
Derivative, notional amount	'	'	'	$64,378	'	$20,000	$11,250
Unrealized gains (losses) on hedging activities	'	'	'	381	-61	'	'
Derivative, expiration date	'	'	'	'	'	31-Dec-15	'
Unrealized loss on interest rate swap	227	'	'	'	'	'	'
Contingent consideration at fair value	'	$5,473	$5,346	'	'	'	'

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Detail) (USD $)	Sep. 30, 2013		Jun. 30, 2013
In Thousands, unless otherwise specified	Sep. 30, 2013		Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency contracts-assets	$461	[1]	$14	[2]
Foreign currency contracts-liabilities	81	[3]	173	[4]
Derivative liability for interest rate swap	227	[5]	258	[6]
Contingent consideration	5,473	[7]	5,346	[8]
Bank Time Deposits [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash equivalents	867		856
Investments	2,165		2,144
Fair Value, Inputs, Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency contracts-assets	461	[1]	14	[2]
Foreign currency contracts-liabilities	81	[3]	173	[4]
Derivative liability for interest rate swap	227	[5]	258	[6]
Fair Value, Inputs, Level 2 [Member] \| Bank Time Deposits [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash equivalents	867		856
Investments	2,165		2,144
Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration	$5,473	[7]	$5,346	[8]

[1]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
[2]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
[3]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
[4]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
[5]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
[6]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.
[7]	$3,000 included in "Accrued expenses" and $2,473 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
[8]	$1,500 included in "Accrued expenses" and $3,846 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.

Fair_Value_Measurements_Schedu1

Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Parenthetical) (Detail) (USD $)	Sep. 30, 2013		Jun. 30, 2013
In Thousands, unless otherwise specified	Sep. 30, 2013		Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration	$5,473	[1]	$5,346	[2]
Accrued Expenses [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration	3,000		1,500
Long-term Liabilities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration	$2,473		$3,846

[1]	$3,000 included in "Accrued expenses" and $2,473 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2013.
[2]	$1,500 included in "Accrued expenses" and $3,846 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2013.

Segment_Information_Schedule_o

Segment Information (Schedule of Segment Perfomance Measures by Segment) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'
Net sales	$129,261	$111,748
Gross profit	33,734	21,505
Income before income taxes	17,574	7,622
Operating Segments [Member] \| Human Health [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	38,694	26,409
Gross profit	11,141	8,103
Income before income taxes	5,535	3,119
Operating Segments [Member] \| Pharmaceutical Ingredients [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	48,424	40,608
Gross profit	15,262	6,576
Income before income taxes	11,004	2,553
Operating Segments [Member] \| Performance Chemicals [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	42,143	44,731
Gross profit	7,331	6,826
Income before income taxes	3,302	3,085
Unallocated Corporate [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Income before income taxes	($2,267)	($1,135)